Skip to content
Triangle logo TriangleGet started
← Full study record

NCT01344876 · OUTCOME

Treatment Response

Phase I Study of OPB-51602 in Patients With Hematologic Malignancies · Source last updated 2015-06-08

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
participants
Interval / dispersion
Not reported
Time frame
From first dose of study medication to withdrawal examination

What was measured

Assessment of the treatment response was evaluated according to internationally recognized response criteria for multiple myeloma, non-Hodgkin's lymphoma, acute myeloid leukemia, chronic myeloid leukemia. "Response" was defined as at least partial response or partial remission (PR) according to the criteria for efficacy assessment.

Analysis population: Efficacy population included all treated subjects who had received at least 1 dose of study drug. No statistical analysis provided for treatment response.

Groups in this outcome

OPB-51602

OPB-51602: 1, 2, 3, 4 and 6 mg/day oral once daily (QD) in a 4 week cycle OPB-51602: once daily during the treatment period

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
OPB-5160220

Reported measurements

Source class 1
Values in participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
OPB-516020Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        0
denoms
  1. counts
    1. group Id
      OG000
      value
      20
    units
    Participants
description
Assessment of the treatment response was evaluated according to internationally recognized response criteria for multiple myeloma, non-Hodgkin's lymphoma, acute myeloid leukemia, chronic myeloid leukemia. "Response" was defined as at least partial response or partial remission (PR) according to the criteria for efficacy assessment.
groups
  1. description
    OPB-51602: 1, 2, 3, 4 and 6 mg/day oral once daily (QD) in a 4 week cycle OPB-51602: once daily during the treatment period
    id
    OG000
    title
    OPB-51602
param Type
NUMBER
population Description
Efficacy population included all treated subjects who had received at least 1 dose of study drug. No statistical analysis provided for treatment response.
reporting Status
POSTED
time Frame
From first dose of study medication to withdrawal examination
title
Treatment Response
type
SECONDARY
unit Of Measure
participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice